EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma

Alexander P Boardman, Juan Luis Reguera Ortega, Pearl Wang, Merav Bar, Jinender Kumar, Thalia Farazi, Alejandro Martín García-Sancho, Koji Izutsu

Advances in Therapy · 2026-07 · 43 (7) · 3204-3229

DOI: 10.1007/s12325-026-03596-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Advances in Therapy, online erschienen am 15.05.2026. Verfasst von Alexander P Boardman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, 530 East 74th Street, New York, NY, 10021, USA. BoardmaA@mskcc.org. Hauptthemen laut MEDLINE: Antigens, CD19, Biological Products, Cancer Vaccines, Immunotherapy, Adoptive. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Bristol Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, CD19Biological ProductsCancer VaccinesImmunotherapy, AdoptiveLymphoma, FollicularReceptors, Antigen, T-CellHumansNeoplasm Recurrence, LocalClinical Trials as Topic

Stichwörter der Autor:innen

Axicabtagene ciloleucelCAR T cell therapyELARAFollicular lymphomaIndirect treatment comparisonLisocabtagene maraleucelMatching-adjusted indirect comparisonTRANSCEND FLTisagenlecleucelZUMA-5

Substanzen

Antigens, CD19axicabtagene ciloleucelBiological ProductsCancer VaccinesReceptors, Antigen, T-Celltisagenlecleucel

Autor:innen und Institutionen

  • Memorial Sloan Kettering Cancer Center, 530 East 74th Street, New York, NY, 10021, USA. BoardmaA@mskcc.org.
  • Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Seville, Spain.
  • EVERSANA, Burlington, ON, Canada.
  • Bristol Myers Squibb, Boudry, Switzerland.
  • Bristol Myers Squibb, Princeton, NJ, USA.
  • Bristol Myers Squibb, San Francisco, CA, USA.

Förderung

  • NCI NIH HHS
  • Bristol Myers Squibb

Zitieren

APA

Boardman, A. P., Reguera Ortega, J. L., Wang, P., Bar, M., Kumar, J., Farazi, T., Martín García-Sancho, A., & Izutsu, K. (2026). Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. Advances in Therapy, 43(7), 3204-3229. https://doi.org/10.1007/s12325-026-03596-2

Vancouver

Boardman AP, Reguera Ortega JL, Wang P, Bar M, Kumar J, Farazi T, et al. Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma. Advances in Therapy. 2026;43(7):3204-3229. doi:10.1007/s12325-026-03596-2

BibTeX
@article{Boardman2026,
  author = {Boardman, Alexander P and Reguera Ortega, Juan Luis and Wang, Pearl and Bar, Merav and Kumar, Jinender and Farazi, Thalia and Martín García-Sancho, Alejandro and Izutsu, Koji},
  title = {Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma},
  journal = {Advances in Therapy},
  year = {2026},
  volume = {43},
  number = {7},
  pages = {3204--3229},
  doi = {10.1007/s12325-026-03596-2}
}
Kostenlos starten →